NUVL – nuvalent, inc. - class a (US:NASDAQ)
Stock Stats
News
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum [Yahoo! Finance]
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $100.00 price target on the stock.
Nuvalent, Inc. (NASDAQ: NUVL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Form 4 Nuvalent, Inc. For: Mar 27 Filed by: Noci Darlene
Form 4 Nuvalent, Inc. For: Mar 17 Filed by: Porter James Richard
Form 4 Nuvalent, Inc. For: Mar 06 Filed by: Noci Darlene
Form 144 Nuvalent, Inc. Filed by: Noci Darlene
Form S-8 Nuvalent, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.